HLS THERAPEUTICS INC (HLS.CA) Stock Fundamental Analysis

TSX:HLS • CA40390B1094

4.5 CAD
0 (0%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall HLS gets a fundamental rating of 3 out of 10. We evaluated HLS against 33 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of HLS have multiple concerns. HLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • HLS had negative earnings in the past year.
  • HLS had a positive operating cash flow in the past year.
  • In the past 5 years HLS always reported negative net income.
  • In the past 5 years HLS always reported a positive cash flow from operatings.
HLS.CA Yearly Net Income VS EBIT VS OCF VS FCFHLS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

  • The Return On Assets of HLS (-10.07%) is comparable to the rest of the industry.
  • HLS has a Return On Equity of -22.87%. This is comparable to the rest of the industry: HLS outperforms 48.48% of its industry peers.
Industry RankSector Rank
ROA -10.07%
ROE -22.87%
ROIC N/A
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
HLS.CA Yearly ROA, ROE, ROICHLS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

  • HLS has a better Gross Margin (81.87%) than 100.00% of its industry peers.
  • HLS's Gross Margin has declined in the last couple of years.
  • HLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
HLS.CA Yearly Profit, Operating, Gross MarginsHLS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • HLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • HLS has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HLS has more shares outstanding
  • The debt/assets ratio for HLS has been reduced compared to a year ago.
HLS.CA Yearly Shares OutstandingHLS.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HLS.CA Yearly Total Debt VS Total AssetsHLS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.94, we must say that HLS is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.94, HLS is in line with its industry, outperforming 45.45% of the companies in the same industry.
  • The Debt to FCF ratio of HLS is 4.28, which is a neutral value as it means it would take HLS, 4.28 years of fcf income to pay off all of its debts.
  • HLS has a Debt to FCF ratio of 4.28. This is amongst the best in the industry. HLS outperforms 81.82% of its industry peers.
  • HLS has a Debt/Equity ratio of 0.80. This is a neutral value indicating HLS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.80, HLS is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.28
Altman-Z -0.94
ROIC/WACCN/A
WACC8.13%
HLS.CA Yearly LT Debt VS Equity VS FCFHLS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.17 indicates that HLS should not have too much problems paying its short term obligations.
  • HLS has a worse Current ratio (1.17) than 72.73% of its industry peers.
  • A Quick Ratio of 0.87 indicates that HLS may have some problems paying its short term obligations.
  • HLS has a worse Quick ratio (0.87) than 60.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.87
HLS.CA Yearly Current Assets VS Current LiabilitesHLS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • HLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.78%, which is quite impressive.
  • The Revenue has decreased by -1.92% in the past year.
  • Measured over the past years, HLS shows a small growth in Revenue. The Revenue has been growing by 0.88% on average per year.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-4.08%

3.2 Future

  • HLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.32% yearly.
  • HLS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.53% yearly.
EPS Next Y36.47%
EPS Next 2Y28.13%
EPS Next 3Y24.26%
EPS Next 5Y20.32%
Revenue Next Year-3.29%
Revenue Next 2Y3.26%
Revenue Next 3Y7.08%
Revenue Next 5Y4.53%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HLS.CA Yearly Revenue VS EstimatesHLS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M
HLS.CA Yearly EPS VS EstimatesHLS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HLS. In the last year negative earnings were reported.
  • Also next year HLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLS.CA Price Earnings VS Forward Price EarningsHLS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • HLS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HLS is cheaper than 66.67% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, HLS is valued cheaper than 84.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.12
EV/EBITDA 9.16
HLS.CA Per share dataHLS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HLS's earnings are expected to grow with 24.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.13%
EPS Next 3Y24.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HLS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HLS THERAPEUTICS INC

TSX:HLS (2/20/2026, 7:00:00 PM)

4.5

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-12
Inst Owners42.64%
Inst Owner ChangeN/A
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap140.72M
Revenue(TTM)55.85M
Net Income(TTM)-14.12M
Analysts80
Price Target8.35 (85.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-48.51%
Min EPS beat(2)-69.73%
Max EPS beat(2)-27.3%
EPS beat(4)0
Avg EPS beat(4)-31.47%
Min EPS beat(4)-69.73%
Max EPS beat(4)-11.88%
EPS beat(8)1
Avg EPS beat(8)-25.77%
EPS beat(12)1
Avg EPS beat(12)-56.65%
EPS beat(16)1
Avg EPS beat(16)-50.22%
Revenue beat(2)0
Avg Revenue beat(2)-4.93%
Min Revenue beat(2)-6.61%
Max Revenue beat(2)-3.24%
Revenue beat(4)0
Avg Revenue beat(4)-3%
Min Revenue beat(4)-6.61%
Max Revenue beat(4)-0.17%
Revenue beat(8)1
Avg Revenue beat(8)-4.67%
Revenue beat(12)2
Avg Revenue beat(12)-4.36%
Revenue beat(16)2
Avg Revenue beat(16)-5.03%
PT rev (1m)7.73%
PT rev (3m)22.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40%
EPS NY rev (1m)-1.74%
EPS NY rev (3m)-21.87%
Revenue NQ rev (1m)1.01%
Revenue NQ rev (3m)-6.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.84
P/FCF 8.12
P/OCF 7.43
P/B 1.66
P/tB N/A
EV/EBITDA 9.16
EPS(TTM)-0.62
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)0.55
FCFY12.31%
OCF(TTM)0.61
OCFY13.47%
SpS2.45
BVpS2.71
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.07%
ROE -22.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.87%
FCFM 22.64%
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.28
Debt/EBITDA 3.1
Cap/Depr 5.44%
Cap/Sales 2.12%
Interest Coverage N/A
Cash Conversion 86.75%
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.87
Altman-Z -0.94
F-Score6
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)0.36%
Cap/Depr(5y)20.34%
Cap/Sales(3y)0.19%
Cap/Sales(5y)11.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y36.47%
EPS Next 2Y28.13%
EPS Next 3Y24.26%
EPS Next 5Y20.32%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-4.08%
Revenue Next Year-3.29%
Revenue Next 2Y3.26%
Revenue Next 3Y7.08%
Revenue Next 5Y4.53%
EBIT growth 1Y47.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year285.58%
EBIT Next 3Y67.3%
EBIT Next 5Y42.36%
FCF growth 1Y-17.8%
FCF growth 3Y-20.24%
FCF growth 5Y-19.65%
OCF growth 1Y-11.25%
OCF growth 3Y-21.32%
OCF growth 5Y-21.24%

HLS THERAPEUTICS INC / HLS.CA FAQ

Can you provide the ChartMill fundamental rating for HLS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA.


What is the valuation status for HLS stock?

ChartMill assigns a valuation rating of 3 / 10 to HLS THERAPEUTICS INC (HLS.CA). This can be considered as Overvalued.


What is the profitability of HLS stock?

HLS THERAPEUTICS INC (HLS.CA) has a profitability rating of 2 / 10.


How sustainable is the dividend of HLS THERAPEUTICS INC (HLS.CA) stock?

The dividend rating of HLS THERAPEUTICS INC (HLS.CA) is 0 / 10 and the dividend payout ratio is 0%.